Free Trial

Mind Medicine (MindMed) (MNMD) Stock Forecast & Price Target

Mind Medicine (MindMed) logo
$7.56 +0.47 (+6.63%)
(As of 11/22/2024 ET)

Mind Medicine (MindMed) - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
12

Based on 12 Wall Street analysts who have issued ratings for Mind Medicine (MindMed) in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 9 have given a buy rating, and 3 have given a strong buy rating for MNMD.

Consensus Price Target

$25.38
235.65% Upside
According to the 12 analysts' twelve-month price targets for Mind Medicine (MindMed), the average price target is $25.38. The highest price target for MNMD is $55.00, while the lowest price target for MNMD is $9.00. The average price target represents a forecasted upside of 235.65% from the current price of $7.56.
Get the Latest News and Ratings for MNMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Mind Medicine (MindMed) and its competitors.

Sign Up

MNMD Analyst Ratings Over Time

TypeCurrent Forecast
11/24/23 to 11/23/24
1 Month Ago
10/25/23 to 10/24/24
3 Months Ago
8/26/23 to 8/25/24
1 Year Ago
11/24/22 to 11/24/23
Strong Buy
3 Strong Buy rating(s)
3 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$25.38$25.38$24.14$25.43
Forecasted Upside235.65% Upside315.30% Upside301.04% Upside742.01% Upside
Consensus Rating
Buy
Buy
Buy
Buy

MNMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MNMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Mind Medicine (MindMed) Stock vs. The Competition

TypeMind Medicine (MindMed)Medical CompaniesS&P 500
Consensus Rating Score
3.25
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside235.65% Upside26,878.84% Upside7.66% Upside
News Sentiment Rating
Positive News

See Recent MNMD News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$55.00 ➝ $55.00+547.82%
10/14/2024Leerink Partners
1 of 5 stars
 Initiated CoverageOutperform$20.00+266.30%
10/11/2024Leerink Partnrs
5 of 5 stars
M. Goodman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/16/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$16.00 ➝ $14.00+122.58%
7/24/2024Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Wittes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/24/2024Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy ➝ Buy$36.00 ➝ $36.00+307.24%
6/21/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
6/5/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$22.00 ➝ $22.00+212.94%
5/29/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Beatty
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/28/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$27.00+223.35%
5/13/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$29.00 ➝ $20.00+121.24%
4/14/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$21.00+510.46%
12/15/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$21.00+701.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:04 PM ET.


MNMD Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Mind Medicine (MindMed) is $25.38, with a high forecast of $55.00 and a low forecast of $9.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last twelve months. There are currently 9 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNMD shares.

According to analysts, Mind Medicine (MindMed)'s stock has a predicted upside of 235.65% based on their 12-month stock forecasts.

Over the previous 90 days, Mind Medicine (MindMed)'s stock had 1 upgrade by analysts.

Mind Medicine (MindMed) has been rated by research analysts at Canaccord Genuity Group, HC Wainwright, Leerink Partners, and Leerink Partnrs in the past 90 days.

Analysts like Mind Medicine (MindMed) more than other "medical" companies. The consensus rating for Mind Medicine (MindMed) is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MNMD compares to other companies.


This page (NASDAQ:MNMD) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners